Literature DB >> 2466418

Landau-Kleffner syndrome. EEG topographic studies.

S Nakano1, T Okuno, H Mikawa.   

Abstract

Spectral and historical topographic mapping of EEG was done on 2 siblings with Landau-Kleffner syndrome. The clinical features of the elder sister were acquired aphasia developed at the age of 5, followed by convulsions a year later, and those of the younger brother were progressive ataxia, hemiparesis, urinary incontinence and convulsions at the age of 4 years and 10 months, followed by acquired aphasia a year later. The most prominent spectral mapping features were high spectral powers of delta, theta and alpha waves over the fronto-centro-parietal area. The power of alpha and beta wave bands, reflecting sharp or spike waves, varied spatio-temporally over the central, parietal, temporal and frontal areas. The historical mapping revealed variabilities of paroxysmal discharges in modes of propagation. These results suggested that electrophysiological dysfunction of the fronto-centro-parietal areas associated with markedly unstable paroxysmal discharges is the main feature of Landau-Kleffner syndrome.

Entities:  

Mesh:

Year:  1989        PMID: 2466418     DOI: 10.1016/s0387-7604(89)80008-7

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  4 in total

Review 1.  Epileptic encephalopathies: new genes and new pathways.

Authors:  Sahar Esmaeeli Nieh; Elliott H Sherr
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 2.  Current Treatment Options for Early-Onset Pediatric Epileptic Encephalopathies.

Authors:  Rolla Shbarou
Journal:  Curr Treat Options Neurol       Date:  2016-10       Impact factor: 3.598

3.  The Landau-Kleffner Syndrome.

Authors:  Phillip L. Pearl; Enrique J. Carrazana; Gregory L. Holmes
Journal:  Epilepsy Curr       Date:  2001-11       Impact factor: 7.500

Review 4.  The Landau-Kleffner Syndrome: a review.

Authors:  S E Mouridsen
Journal:  Eur Child Adolesc Psychiatry       Date:  1995-10       Impact factor: 4.785

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.